Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 9/20 | 0.50 |
| ▸ | LIPG | Q9Y5X9 | 9/20 | 0.50 |
| ▸ | CA2 | P00918 | 2/20 | 0.39 |
| ▸ | ENPP2 | Q13822 | 3/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | PGK1 | P00558 | 1/20 | 0.33 |
| ▸ | PGK2 | P07205 | 1/20 | 0.33 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.33 |
| ▸ | MGLL | Q99685 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.32 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.32 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3791528 | 0.86 | LPL (0.58) | LPLLIPGCA2ENPP2CA1 | |
| SCHEMBL21787203 | 0.86 | LPL (0.58) | LPLLIPGCA2ENPP2CA1 | |
| SCHEMBL16021767 | 0.83 | ENPP2 (0.50) | LPLLIPGCA2ENPP2CA1 | |
| SCHEMBL6699947 | 0.81 | LPL (0.38) | LPLLIPGCA2ENPP2CA1 | |
| SCHEMBL7657848 | 0.78 | CA2 (0.52) | LPLLIPGCA2ENPP2CA1 | |
| SCHEMBL364635 | 0.78 | CA2 (0.52) | LPLLIPGCA2ENPP2CA1 | |
| SCHEMBL12714563 | 0.78 | ALDH1A1 (0.39) | LPLLIPGCA2ENPP2 | |
| SCHEMBL3786679 | 0.77 | LPL (0.48) | LPLLIPGCA2ENPP2CA1 | |
| SCHEMBL12247400 | 0.77 | LPL (0.48) | LPLLIPGCA2ENPP2CA1 | |
| SCHEMBL10136924 | 0.77 | LPL (0.49) | LPLLIPGCA2ENPP2CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210347797-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORPORATION (US) | 2021-11-11 | — | — | US | disclosed |
| EP-3626724-A1 | ORGANOMETALLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME, AND DIAGNOSTIC COMPOSTION INCLUDING THE ORGANOMETALLIC COMPOUND | Samsung Electronics Co., Ltd. (KR) | 2020-03-25 | — | — | EP | disclosed |
| US-20200091441-A1 | ORGANOMETALLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME, AND DIAGNOSTIC COMPOSTION INCLUDING THE ORGANOMETALLIC COMPOUND | SAMSUNG ELECTRONICS CO LTD (KR) | 2020-03-19 | — | — | US | disclosed |
| US-20100087680-A1 | METHOD FOR PRODUCING BIARYL COMPOUND | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 2010-04-08 | — | — | US | disclosed |
| EP-1914221-A1 | PROCESS FOR PRODUCING BIARYL COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2008-04-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200091441-A1 | ORGANOMETALLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME, AND DIAGNOSTIC COMPOSTION INCLUDING THE ORGANOMETALLIC COMPOUND | NOM1, L1CAM, MEN1 | LPL 2094/4885LIPG 3544/4885CA2 3071/4885 |
| US-20100087680-A1 | METHOD FOR PRODUCING BIARYL COMPOUND | NISCH, BLVRB, BBOX1 | LPL 3816/4885LIPG 3010/4885CA2 1992/4885 |
| US-20210347797-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | OCIAD2, OCIAD1, TPO | LPL 374/4885LIPG 1080/4885CA2 4046/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.